Catalent has entered an agreement to acquire Cook Pharmica LLC, a provider of drug substance and drug product manufacturing and related services, for $950 million in cash, with $750 million to be paid at closing and the balance to be paid in installments. The acquisition expands Catalent’s position in biologics development and analytical services, manufacturing, and finished product supply. Privately held, Cook Pharmica has capabilities across biologics development, clinical and commercial ce...